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hazard function were run to estimate time to thresholds
of vision loss. The resulting hazards were used to inform
transition probabilities in a Markov model, to estimate
effects (discounted at 3%) for an average patient. RE-
SULTS: The estimate of vision years gained was 0.57
during the trial, and 0.82 at 5 years. Benefits decreased
with age and baseline visual acuity. CONCLUSION:
Based on one year data, the majority of benefit was esti-
mated to accrue within the trial time frame, and benefits
differ across subgroups. Treatment costs may be offset by
delaying costs of blindness.
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A key purpose in conducting pharmacoeconomic (PE)
and health outcomes (HO) research is to aid in the deci-
sion-making process. However, surprisingly few studies
within the literature have evaluated the relevance of this
information to decision-makers. OBJECTIVES: The pur-
pose of this study was to evaluate the relevance of PE and
HO information to health plan decision-makers in man-
aging the pharmacy benefit. METHODS: A qualitative
research method using telephone interviews on a conve-
nience sample of managed care and PBM decision-mak-
ers was used. Participants were presented with 16 hypo-
thetical statements incorporating key PE and HO concepts
and asked to judge the relevance of the statements. Re-
spondents were also prompted to provide a rationale for
their judgement. Questions relating to respondent’s train-
ing and familiarity with PE concepts were also included.
RESULTS: Over 80% of respondents (n  16) were
pharmacists, with one-third working for PBMs. State-
ments related to quality-of-life, cost-of-prevention, cost/
year of life saved, increased life expectancy, and 2-year
savings were relevant to 80% of respondents. Willing-
ness to pay (WTP), cost to society and global cost of ill-
ness statements were considered irrelevant by 35%. Re-
sponse trends to the above indicate that copays preclude
the relevance of WTP information; societal perspectives
are generally not relevant to benefit management, and
plan demographics are more relevant than global demo-
graphics. Statements related to PE modeling were rele-
vant provided that inputs and assumptions were perti-
nent to the user. Statements reported in terms of quality
adjusted life year were difficult for respondents to con-
ceptualize. CONCLUSIONS: These findings suggest that
some PE and HO information is more relevant than oth-
ers in the management of the pharmacy benefit.
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The pharmaceutical industry (PI) is a principal provider
of pharmacoeconomic (PE) data to health care organiza-
tions (HCOs). Therefore, assessing how this information
is perceived and used by HCOs from the PI perspective
can provide insights for future development of PE infor-
mation. OBJECTIVES: The purpose of this study was to
describe the PI perceptions regarding the use of PE infor-
mation by HCOs. METHODS: A structured phone inter-
view was conducted with PI personnel who routinely in-
teract with HCOs, including account managers, scientific
liaisons, and PE/outcomes research managers. Partici-
pants were asked to comment with regard to the fre-
quency of use and importance of various types of PE in-
formation that is provided to HCOs. RESULTS: A total
of 21 subjects were interviewed. About 95% stated that
the PE information provided to HCOs in the previous
year was helpful. The majority of respondents (76%)
stated PE information was considered by HCOs for most
or some decisions. There was significant variation when
asked whether PE articles were relevant, credible, and un-
derstandable to HCOs. Reprints of PE data and HCO-
specific information were most commonly listed as best-
received by HCOs. A majority (81%) also felt there were
barriers to using PE information in HCOs; “isolated fo-
cus on the pharmacy budget” was listed as the most com-
mon barrier. Only one-third of respondents felt their
company met the PE needs of HCOs. The remainder
listed lack of PE information as the primary cause for not
meeting the PE needs of HCOs. CONCLUSION: While
respondents felt that PE information is commonly used
and is perceived as valuable, this study has identified po-
tential limitations to the currently available information.
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Much emphasis is currently being placed on determining
the proper methodology for conducting economic analy-
ses of pharmaceuticals. However, perhaps equally impor-
tant is the need for consideration of how this information
is actually being used by decision-makers. The most re-
cent examination of this issue occurred in 1996. OBJEC-
TIVES: The purpose of this study was to increase our un-
derstanding of how pharmacoeconomic information is
used by decision-makers in managed care and to identify
perceived strengths and weaknesses of the available in-
formation given the current state of the pharmacy bene-
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fit. METHODS: A semi-structured phone survey of man-
aged care decision-makers was conducted between
September and October, 1999. This survey consisted of
approximately 50 questions. Descriptive statistics were
generated. RESULTS: About 30% of participants worked
for a PBM and 70% for various types of HMOs. Phar-
macoeconomic information was most commonly (53%)
used to add a drug to the formulary. Approximately 25%
of respondents found studies difficult to understand and
irrelevant to their organization. Frequently suggested ar-
eas for improvement included more rigorous methods
and development of standardization. Cardiovascular dis-
ease was considered one of the most relevant diseases for
pharmacoeconomic analysis because of its impact on
morbidity, mortality, and cost. Most respondents (71%)
experienced barriers to using pharmacoeconomic infor-
mation. More than 70% stated there was pharmaco-
economic information they desired but is unavailable.
CONCLUSIONS: While decision-makers are using phar-
macoeconomic information and most find it helpful to
their organization, many question the relevance of the
available data, and experience barriers to using pharma-
coeconomic information. This study provides numerous
insights for enhancing the value of pharmacoeconomic
data to decision-makers.
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The applicability of pharmacoeconomic research in deci-
sion-making continues to be an issue of critical impor-
tance. While some research has examined this issue, stud-
ies have consisted of very small sample sizes, prohibiting
generalizable conclusions. OBJECTIVE: The objective of
this study was to examine how decision-makers in health
plans view and use pharmacoeconomic information in
a large and geographically diverse population. METH-
ODS: A random sample of 3000 Formulary subscribers
who were pharmacists or physicians working in a health
care organization (non-institutional) was identified. Sub-
jects were randomized to three different groups of 1000
with a different survey mailed to each group. A notifica-
tion postcard, reminder postcard, and follow-up survey
were sent, for an anticipated response rate of 30%. RE-
SULTS: While data collection is still in progress, analysis
of surveys inputted to date (n  241) indicate that re-
spondents represent the majority of states, 66% serve on
P&T committees, 78% are pharmacists, and the majority
work for HMOs. While 90% of respondents are consid-
ering pharmacoeconomic information in their decision-
making, 20% rarely or never act upon this information
while two-thirds occasionally do. About 25% said that if
pharmacoeconomic studies were no longer published,
this would have little or no effect on their organization,
and 60% said it would have some effect. Respondents
identified therapy classes for which pharmacoeconomics
is most and least relevant. They identified the value of
various sources of pharmacoeconomic information, study
types, and specific journals and indicated various barriers
to the use of pharmacoeconomic information. CON-
CLUSIONS: These results provide insight into how to
better develop and target pharmacoeconomic informa-
tion to managed care decision-makers.
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OBJECTIVES: The objectives of this study were (1) to
oversee patients, pharmacists, and other health profes-
sional’s satisfactions of traditional hospital pharmacy
services at Barbados, West Indies. (2) To evaluate
whether or not the unit dose machine will improve effi-
ciency and productivity for the hospital without increas-
ing health expenditure. SETTING: The study setting is a
600-bed community hospital located at Barbados, West
Indies. It is the only hospital on this 250,000-population
island. METHODS: Three surveys among patients, phar-
macists, and health professionals were used to assess
their opinion on the performance of the Pharmacy. Next,
we evaluated the cost saving of using unit dose machine
and unit dose carts for the hospital. RESULTS: The sur-
veys showed that most of the patients (n  200) and
health professionals (n  100) were dissatisfied with the
wait time. And most pharmacists were looking for ways
to improve their functions and services. Using the
ANOVA statistics to compare seven health professionals’
opinions on the wait time (P  0.01), the convenience of
pharmacy services (P  0.019) and improving the effi-
ciency of the pharmacy by use of the computer (P 
0.047) showed statistically significant difference. The
drug expenditure in this hospital for 1998 was 7.1 mil-
lion dollars. It is proposed that the hospital might be able
to save approximately $1,420,000 per year (20% sav-
ing), which would be able to pay for the new equipments
and the cost of improvements. CONCLUSION: The
study found that the use an automation system along
with a computer system could reduce both the cost of
medication, while improving productivity and quality
of work.
